All articles by GlobalData Healthcare

Metabolomic signatures strengthen association between diet and cancer risk in women

Cancer is a leading cause of death worldwide, with the World Health Organization (WHO) estimating that cancer accounts for approximately…
Saturated fat increases the risk of mortality in non-metastatic prostate cancer

In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third…
ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial

At the European Respiratory Society (ERS) Congress 2026, investigators from AstraZeneca and collaborating institutions presented the company's Phase IIb PRESTO…
ERS 2026: Brensocatib cuts NCFB exacerbations in NTM history patients

On September 6, at the European Respiratory Society (ERS) Congress 2026, Insmed presented results from a post hoc analysis from…
ERS 2026: Sanofi’s lunsekimig hits Phase IIb goals in asthma, Phase III set to follow

On September 7, during the European Respiratory Society (ERS) Congress in Barcelona, Sanofi presented detailed efficacy and safety data from…

ERS 2026: Phase Ib/IIa results support further evaluation of 9MW1911 in COPD

At the European Respiratory Society (ERS) Congress 2026, Mabwell and collaborating institutions presented results from the Phase Ib/IIa 9MW1911 study…
ERS 2026: tozorakimab’s groundbreaking exacerbation reduction sets a new bar in COPD

On September 8, at the European Respiratory Society (ERS) Congress in Barcelona, AstraZeneca presented full results from its Phase III…
MRSA therapeutics market to reach $1.8bn across 7MM in 2034

The methicillin-resistant Staphylococcus aureus (MRSA) therapeutics market across the seven major pharmaceutical markets (7MM), comprising the US, 5EU (France, Germany,…
Can CNS trial momentum convert into late-stage evidence?

The central nervous system (CNS) remains one of biopharma’s most strategically important therapy areas in 2026, but GlobalData’s clinical trials…
Narcolepsy market expected to reach $7.8bn across 7MM by 2035

The narcolepsy market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is…